Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I5HF
|
|||
| Former ID |
DCL000438
|
|||
| Drug Name |
Apixaban
|
|||
| Synonyms |
GG2; BMS 562247-01; BMS-562247; Eliquis (TN); BMS-562247-01; Apixaban (JAN/USAN/INN); BMS-562247-01, Apixaban; Ro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide; 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahyd
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Thrombosis [ICD-11: DB61-GB90; ICD-10: I80-I82] | Approved | [1], [2] | |
| Company |
Pfizer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H25N5O4
|
|||
| Canonical SMILES |
COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N
|
|||
| InChI |
1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32)
|
|||
| InChIKey |
QNZCBYKSOIHPEH-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 503612-47-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
15178464, 17397366, 22578033, 26736936, 40272539, 46519072, 51992439, 53812906, 56310620, 57374335, 99375349, 99444299, 103535612, 104253239, 109693404, 124757362, 124772059, 125164166, 125433570, 126644898, 126665798, 134339057, 135252374, 135727449, 135727826, 136367462, 136368094, 136920385, 137183704, 139455355, 144115617, 152258806, 152343992, 152344098, 160647657, 160874191, 160962913, 160968889, 162011738, 163884621, 164194092, 164777207, 165247616, 170497908, 172912849, 174006823, 174549337, 175266926, 175427077, 178103006
|
|||
| ChEBI ID |
CHEBI:72296
|
|||
| ADReCS Drug ID | BADD_D00151 | |||
| SuperDrug ATC ID |
B01AF02
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Coagulation factor Xa (F10) | Target Info | Inhibitor | [3], [4] |
| KEGG Pathway | Complement and coagulation cascades | |||
| Panther Pathway | Blood coagulation | |||
| Pathwhiz Pathway | Coagulation | |||
| Pathway Interaction Database | Beta2 integrin cell surface interactions | |||
| Reactome | Extrinsic Pathway of Fibrin Clot Formation | |||
| Intrinsic Pathway of Fibrin Clot Formation | ||||
| Common Pathway of Fibrin Clot Formation | ||||
| Gamma-carboxylation of protein precursors | ||||
| Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus | ||||
| Removal of aminoterminal propeptides from gamma-carboxylated proteins | ||||
| WikiPathways | Complement and Coagulation Cascades | |||
| Human Complement System | ||||
| PTM: gamma carboxylation, hypusine formation and arylsulfatase activation | ||||
| Blood Clotting Cascade | ||||
| Formation of Fibrin Clot (Clotting Cascade) | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6390). | |||
| REF 2 | Nat Rev Drug Discov. 2013 Feb;12(2):87-90. | |||
| REF 3 | Pfizer. Product Development Pipeline. March 31 2009. | |||
| REF 4 | Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays. J Thromb Haemost. 2014 Sep;12(9):1545-53. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.